In vitro, farletuzumab mediates complement-dependent and antibody-dependent cytotoxicity in tumor cell lines and inhibits FRα-dependent cell growth in CHO cells over-expressing the receptor [9]. The gene discussed is FOLR1; the disease is neoplasm.